

April 1st, 2025

CURRICULUM VITAE
Yusuke SHONO, M.D., Ph.D.

TABLE OF CONTENTS

Education and Training	2
Certification and Licensure	2
Academic and Clinical Appointments	
Academic	3
Clinical	3
Research Interests.....	4
Grants	
Previous.....	4
Honors and Awards	6
Memberships in Professional Societies.....	6
Teaching	7
Seminars and Extramural Invited Presentation	
Extramural Invited Presentations	7
Abstract/Manuscript Reviewer.....	7
Patent.....	8
Bibliography	8
Peer-Reviewed Publications.....	8

DATE AND PLACE OF BIRTH: 08/02/1977, Sapporo, Hokkaido, Japan

SEX: Male

CITIZENSHIP: Japan

EDUCATION AND TRAINING

Education

Apr 1997-Mar 2003 Hokkaido University School of Medicine, Japan
Bachelor of Medicine (Top Honors)

Apr 2006-Jun 2010 Hokkaido University Graduate School of Medicine, Japan /
Graduate School of Medicine, The University of Tokyo, Japan
Ph.D. Medical Research (Hematology/Oncology)

Training

Apr 2003-Mar 2004 Resident in Internal Medicine,
Hokkaido University Hospital, Sapporo, Japan

Apr 2004-Mar 2005 Resident in Internal Medicine,
Asahikawa City Hospital, Asahikawa, Japan

Apr 2005-Mar 2006 Fellowship in Internal Medicine (Hematology and Oncology,
Hematopoietic Cell Transplantation),
Sapporo Hokuyu Hospital, Sapporo, Japan

July 2017-June 2020 Resident, Department of Medicine,
SUNY Downstate Medical Center, Brooklyn, NY, USA

CERTIFICATION AND LICENSURE

Certifications

Sep 2006-Present Fellow of the Japanese Society of Internal Medicine

Apr 2009-Present Board Certified Member of the Japanese Society of Hematology

Mar 2016 ECFMG Certification (No. 0-647-597-4)

License

May 2003 Japanese Medical Doctor License (No. 432536)

June 2019 ACLS Provider (No. 07120111801)

ACADEMIC AND CLINICAL APPOINTMENTS

Academic Appointments

Apr 2007-Mar 2009	Visiting Research Fellow, Department of Molecular Preventive Medicine, The University of Tokyo, Tokyo, Japan
Apr 2011-Mar 2013	Research Fellow, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Apr 2013-Jun 2017	Research Associate, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
July 2017-June 2020	Visiting Investigator, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Clinical Appointments

Apr 2003-Mar 2004	Resident in Internal Medicine, Hokkaido University Hospital, Sapporo, Japan
Apr 2004-Mar 2005	Resident in Internal Medicine, Asahikawa City Hospital, Asahikawa, Japan
Apr 2005-Mar 2006	Fellow in Internal Medicine (Hematology and Oncology, Hematopoietic Cell Transplantation), Sapporo Hokuyu Hospital, Sapporo, Japan
Apr 2006-Mar 2007	Physician, Department of Hematology and Oncology, Hokkaido University Hospital, Sapporo, Japan
Apr 2009-Mar 2011	Physician, Department of Hematology and Oncology, Hokkaido University Hospital, Sapporo, Japan
July 2017-June 2020	Clinical Instructor, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA
May 2020-Nov 2022	Physician, Cosmoskai Clinic, Osaka, Japan
August 2020-Nov 2023	Physician, Osaka Infectious Disease Clinic, Osaka, Japan
July 2020-present	Physician, Tamatani Clinic, Osaka, Japan

RESEARCH INTERESTS:

1. Translational Hematopoietic Stem Cell Transplantation (HSCT) immunology; especially immunobiology of Graft-versus-Host Disease (GVHD) and Graft-versus-Leukemia (GVL), focusing on hematopoiesis and immune reconstitution
2. Development of novel therapies for GVHD and relapse after HSCT
3. Anti-CD4 T-cell therapy, CAR T-cell therapy, single-cell TCR analysis
4. Roles of SNPs and microbiota in HSCT

GRANTS

Previous

Sponsor: NIH (New York University School of Medicine)
Role: Research Associate
Title: The role of autophagy gene Atg16L1 in allogeneic hematopoietic stem cell transplantation
Annual direct costs: \$23,000 (salary support)
Total Project Periods: 09/01/15-05/31/20

Sponsor: American Society for Blood and Marrow Transplantation
Role: New Investigator Award
Title: Strategies to overcome transplantation barriers and treat hematologic malignancies enabled by a novel small molecule compound promoting c-Rel/NF-kB inhibition
Annual direct costs: \$30,000
Total Project Periods: 07/01/15-06/30/17

Sponsor: Lymphoma Research Foundation
Role: Post-Doctoral Fellowship
Title: A novel method for graft-versus-host disease prophylaxis without compromising tumor immunity
Annual direct costs: \$50,000-\$55,000
Total Project Periods: 05/01/13-04/30/15

Sponsor: The Uehara Memorial Foundation (Japan)
Role: Fellowship
Title: A project to elucidate the pathophysiology of graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect in allogeneic hematopoietic stem cell transplantation and to develop novel treatments
Annual direct costs: ¥ 4,000,000
Total Project Periods: 04/01/11-03/31/13

Sponsor: The HIROKO International Academic Exchange Foundation (Japan)
Role: Fellowship
Title: Development of a novel therapy for prevention of GVHD
Annual direct costs: ¥ 1,000,000
Total Project Periods: 02/01/11-01/31/12

Sponsor: The ITO Foundation (Japan)
Role: Fellowship
Title: A novel therapy for separation of GVHD and GVT
Annual direct costs: ¥ 200,000
Total Project Periods: 10/01/10-09/30/11

Sponsor: Asian Workshop for Hematopoietic Stem Cell Transplantation (Japan)
Role: Fellowship
Title: Development of a novel therapy for separation of GVHD and GVT
Annual direct costs: ¥ 500,000
Total Project Periods: 06/01/10-05/30/11

HORNORS AND AWARDS

2003	Takakuwa Eimatsu Award
2012	American Society of Hematology Abstract Achievement Award
2013	American Society of Blood and Marrow Transplantation Best Abstract Award
2013	American Society of Hematology Abstract Achievement Award
2014	American Society of Blood and Marrow Transplantation Best Abstract Award
2014	American Society of Hematology Abstract Achievement Award
2014	Hokkaido University Department of Hematology Alumni Association Excellent Paper Award
2015	American Society of Blood and Marrow Transplantation Best Abstract Award
2015	Hokkaido University Medical School Alumni Association Furate Investigator Award

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

2003-Present	Japanese Society of Internal Medicine, Member
2003-Present	Japanese Society of Hematology, Member
2005-Present	Japan Society of Transfusion Medicine and Cell Therapy, Member
2003-Present	Japanese Society of Hematopoietic Cell Transplantation, Member
2003-Present	Japanese Society for Lymphoreticular Tissue Research, Member
2003-Present	Japanese Society of Chemotherapy, Member
2003-Present	Japanese Society for Immunology, Member
2007-Present	American Society of Hematology, Member
2007-Present	European Hematology Association, Member
2008-Present	American Society for Blood and Marrow Transplantation, Member
2003-2011	Japanese Association of Germfree Life and Gnotobiology, Member
2003-2011	Japanese Association of Infectious Disease, Member

2003-2011	Japan Society of Clinical Oncology, Member
2003-2011	Japan Society of Medical Oncology, Member
2003-2011	Japan Geriatrics Society, Member

TEACHING

Mentoring

Summer High School Student Mentor

Jul 2012-Aug 2012	Anika Tripathi, Horace Mann School, Bronx, NY
Jul 2012-Aug 2013	Shara Um, Edgemont High School, Scarsdale, NY
Jul 2015-Aug 2015	Rahul Kukreja, Horace Mann School, Riverdale, NY

SEMINARS AND EXTRAMURAL INVITED PRESENTATIONS

Extramural Invited Presentations

Oct 2010	“Bone Marrow GVHD”, Hematological Conference, Tokyo, Japan
Nov 2011	“Bone Marrow Graft-versus-Host Disease: destruction of hematopoietic niche”, Kyusyu BMT Conference, Fukuoka, Japan
Oct 2016	“Gut microbiota and GVHD”, The 78 th Annual Meeting of the Japanese Society of Hematology, Yokohama, Japan
Nov 2018	“Gut microbiota injury in allogeneic hematopoietic stem cell transplantation”, The 23 rd Annual Congress of APBMT, Taipei, Taiwan
Apr 2019	“Microbiota in allogeneic hematopoietic stem cell transplantation”, China Cancer Immunotherapy and Targeting Therapy Conference & Gaobo Medical Annual Meeting, Beijing, China

ABSTRACT/MANUSCRIPT REVIEWER

Abstract 2014	American Society of Hematology (ASH); Category 702 - Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects
---------------	---

Journals	<i>Blood, Bone Marrow Transplantation, British Journal of Haematology, Clinical Transplantation, Clinical Infectious Disease, EbioMedicine, Journal of Hematology and Oncology, Frontiers in Immunology</i>
----------	---

PATENT

1. IMMUNOLOGICAL RECONSTITUTION PROMOTER OR PROPHYLACTIC AGENT FOR INFECTIONS EACH OF WHICH MAINTAINS GRAFT-VERSUS-TUMOR EFFECT; PCT/JP2009/068805, Kouji Matsushima, Satoshi Ueha, **Yusuke Shono**
2. INTESTINAL MICROBIOTA AND GVHD; PCT/US2015/062734, Marcel van den Brink, Robert Jenq, Eric G Pamer, Yung Taur, **Yusuke Shono**

BIBLIOGRAPHY

Peer-Reviewed Journal and Publications

1. Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, **Shono Y**, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. *Sci Transl Med*, 2022, 14(671):eabo3445.
2. Docampo MD, Burgos da Silva M, Lazrak A, Nichols KB, Lieberman SR, Slingerland AE, Armijo GK, **Shono Y**, Nguyen CL, Monette S, Dwomoh E, Lee N, Geary CD, Perobelli SM, Smith M, Markey KA, Vardhana SA, Kousa AI, Zamir E, Greenfield I, Sun JC, Cross JR, Peled JU, Jenq RR, Stein-Thoeringer C, van den Brink MRM. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease. *Blood*, 2022, 139:2392-2405.
3. Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, Burgos da Silva M, Khan N, Gessner A, Messina JA, Romero K, Lew MV, Bush A, Bohannon L, Brereton DG, Fontana E, Amoretti LA, Wright RJ, Armijo GK, **Shono Y**, Sanchez-Escamilla M, Castillo Flores N, Alarcon Tomas A, Lin RJ, Yáñez San Segundo L, Shah GL, Cho C, Scordo M, Politikos I,

- Hayasaka K, Hasegawa Y, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Jenq RR, Teshima T, Chao NJ, Holler E, Xavier JB, Pamer EG, van den Brink MRM. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. *N Engl J Med*, 2020, 382:822-834.
4. Matsuzawa-Ishimoto Y, Hine A, **Shono Y**, Rudensky E, Lazrak A, Yeung F, Neil JA, Yao X, Chen YH, Heaney T, Schuster SL, Zwack EE, Axelrad JE, Hudesman D, Tsai JJ, Nichols K, Dewan MZ, Cammer M, Beal A, Hoffman S, Geddes B, Bertin J, Liu C, Torres VJ, Loke P, van den Brink MRM, Cadwell K. An intestinal organoid-based platform that recreates susceptibility to T-cell-mediated tissue injury. *Blood*, 2020, 135, 2388-2401.
 5. Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, **Shono Y**, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C8, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T1, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM. Lactose Drives Enterococcus Expansion to Promote Graft-versus-Host Disease. *Science*, 2019, 366:1143–1149.
 6. Tsai JJ, Velardi E, **Shono Y**, Argyropoulos KV, Holland AM, Smith OM, Yim NL, Rao UK, Kreines FM, Lieberman SR, Young LF, Lazrak A, Youssef S, Fu YY, Liu C, Lezcano C, Murphy GF, Na IK, Jenq RR, Hanash AM, Dudakov JA, van den Brink MRM. Nr1h2 regulates CD4⁺ T cell-induced acute graft-versus-host disease in mice. *Blood*, 2018, 132:2763-2774.
 7. Staffas A, Burgos da Silva M, Slingerland AE, Lazrak A, Bare CJ, Holman CD, Docampo MD, **Shono Y**, Durham B, Pickard AJ, Cross JR, Stein-Thoeringer C, Velardi E, Tsai JJ, Jahn L, Jay H, Lieberman S, Smith OM, Pamer EG, Peled JU, Cohen DE, Jenq RR, van den Brink MRM. Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. *Cell Host Microbe*, 2018, 23:447-457.
 8. **Shono Y**, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem

- cell transplantation. *Nat Rev Cancer*, 2018, 18:283-295.
9. Velardi E, Tsai JJ, Radtke S, Cooper K, Argyropoulos KV, Jae-Hung S, Young LF, Lazrak A, Smith OM, Lieberman S, Kreines F, **Shono Y**, Wertheimer T, Jenq RR, Hanash AM, Narayan P, Lei Z, Moore MA, Kiem HP, van den Brink MRM, Dudakov JA. Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. *Nat Med*, 2018, 24:239-246.
 10. Wertheimer T, Velardi E, Tsai J, Cooper K, Xiao S, Kloss CC, Ottmüller KJ, Mokhtari Z, Brede C, deRoos P, Kinsella S, Palikuqi B, Ginsberg M, Young LF, Kreines F, Lieberman SR, Lazrak A, Guo P, Malard F, Smith OM, **Shono Y**, Jenq RR, Hanash AM, Nolan DJ, Butler JM, Beilhack A, Manley NR, Rafii S, Dudakov JA, van den Brink MRM. Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. *Sci Immunol*, 2018, 12: eaal2736.
 11. Kosugi-Kanaya M, Ueha S, Abe J, Shichino S, Shand FHW, Morikawa T, Kurachi M, **Shono Y**, Sudo N, Yamashita A, Suenaga F, Yokoyama A, Yong W, Imamura M, Teshima T, Matsushima K. Long-Lasting Graft-Derived Donor T Cells Contribute to the Pathogenesis of Chronic Graft-versus-Host Disease in Mice. *Front. Immunol*, 2017, 8:1842.
 12. **Shono Y**, van den Brink MRM. Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage? *Blood Adv*, 2017, 1:2325-2328.
 13. Matsuzawa-Ishimoto Y*, **Shono Y***, Gomez LE, Hubbard-Lucey VM, Cammer M, Neil J, Dewan MZ, Lieberman SR, Lazrak A, Marinis JM, Beal A, Harris PA, Bertin J, Liu C, Ding Y, van den Brink MR**, Cadwell K**. Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium. *J Exp Med*, 2017, 214:3687-3705. ***shared first authorship**, **shared last authorship.
 14. Ueha S, Yokochi S, Ishiwata Y, Kosugi-Kanaya M, **Shono Y**, Shibayama S, Ito S, Matsushima K. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. *Cancer Sci*, 2017, 108:1967-1973.
 15. Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, **Shono Y**,

- Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM*, Poeck H*. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. *Sci Trans Med*, 2017, 9: eaag2513. *shared last authorship.
16. Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, **Shono Y**, Slingerland AE, Docampo MD, Sung AD, Weber D, Alousi AM, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Taur Y, Pamer EG, Jenq RR*, van den Brink MR*. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. *J Clin Oncol*, 2017, 35:1650-1659. *shared last authorship.
 17. **Shono Y**, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Rodriguez KAP, Xu K, Calarfiore M, Poeck H, Caballero S, Devlin SM, Rapaport F, Dudakov JA, Hanash AM, Gyurkocza B, Murphy GF, Gomes CG, Liu C, Moss EL, Falconer SB, Bhatt AS, Taur Y, Pamer EG, van den Brink MR*, Jenq RR*. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in mice and human patients. *Sci Transl Med*, 2016, 8:339ra71. *shared last authorship. (Featured in *Science* 2016, 352:949-950, *Healio*, *Medical Daily*, *TheScientist*, and *EurekAlert*).
 18. Mathewson N, Jenq R, Mathew A, Koenigsnecht M, Hanash A, Toubai T, Oravec-Wilson K, Wu SH, Sun Y, Rossi C, Fujiwara H, Byun J, **Shono Y**, Lindemans C, Calafiore M, Schmidt T, Honda K, Young V, Pennathur S, van den Brink MR, Reddy P. Gut microbiome derived metabolites modulate intestinal epithelial cell damage and mitigate Graft-versus-Host Disease. *Nat Immunol*, 2016, 17:505-513.
 19. **Shono Y**, Tuckett AZ, Liou HC, Doubrovina E, Derenzini E, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CGK, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR*, Zakrzewski JL*. Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-kB-controlled oxidative stress responses. *Cancer Res*, 2016, 76:377-389. *shared last authorship.
 20. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L6, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK,

- Lumish MA, **Shono Y**, Dudakov JA, Poeck H, Hanash AM, Barker JN, Perales MA, Giralt SA, Pamer EG, van den Brink MR. Intestinal Blautia is associated with reduced death from graft-versus-host disease. *Biol Blood Marrow Transplant* 2015, 21:1373-1383.
21. **Shono Y**, Docampo MD, Peled JU, Perobelli SM, Jenq RR. Intestinal microbiota-related effects on graft-versus-host disease. *Int J Hematol* 2015, 101:428-437.
 22. Suenaga F, Ueha S, Abe J, Kosugi-Kanaya M, Wang Y, Yokoyama A, **Shono Y**, Shand FH, Morishita Y, Kunisawa J, Sato S, Kiyono H, Matsushima K. Loss of Lymph Node Fibroblastic Reticular Cells and High Endothelial Cells Is Associated with Humoral Immunodeficiency in Mouse Graft-versus-Host Disease. *J Immunol* 2015, 194: 398-406.
 23. Hubbard-Lucey VM*, **Shono Y***, Maurer K, West ML, Singer NV, Ziegler CGK, Lezcano C, Motta ACF, Schmid K, Levi SM, Murphy GF, Liu C, Winkler JD, Amaravadi RK, Rogler G, Dickinson AM, Holler E, van den Brink MR**, Cadwell K**. Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells. *Immunity* 2014, 41:579-591. ***shared first authorship**, **shared last authorship.
 24. Tuckett AZ, Thornton RH, **Shono Y**, Smith OM, Levy E, Kreines F, van den Brink MR, Zakrzewski JL: Image-guided intrathymic injection of multipotent stem cells supports life-long T cell immunity and facilitates targeted immunotherapy. *Blood* 2014, 123:2797-2805.
 25. **Shono Y**, Tuckett AZ, Ouk S, Liou HC, Altan-Bonnet G, Tsai JJ, Oyler JE, Smith OM, West ML, Singer NV, Doubrovina E, Pankov D, Undhad CV, Murphy GF, Lezcano C, Liu C, O'Reilly RJ, van den Brink MR*, Zakrzewski JL*. A small molecule c-Rel inhibitor reduces alloactivation of T-cells without compromising anti-tumor activity. *Cancer Discov* 2014, 4:578-591. *shared last authorship.
 26. **Shono Y***, Shiratori S*, Kosugi-Kanaya M, Ueha S, Sugita J, Shigematsu A, Kondo T, Hashimoto D, Fujimoto K, Endo T, Nishio M, Hashino S, Matsuno Y, Matsushima K, Tanaka J, Imamura M, Teshima T. Bone Marrow graft-versus-host disease: evidence of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation *Biol Blood Marrow Transplant* 2014, 20:495-500. ***shared first authorship** (Featured in *Global Medical Discovery* 2014).
 27. Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, **Shono Y**, Ghosh A, Hanash AM, Tran HT, Moore MA, van

- den Brink MR. Nrf2 regulates haematopoietic stem cell function. *Nat Cell Biol* 2013, 15:309-316.
28. Toubai T, Tanaka J, Paczesny S, **Shono Y**, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD) – Are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT)? *Curr Stem Cell Res Ther* 2012, 7:229-239.
 29. Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, Shiratori S, Ibata M, **Shono Y**, Shigematsu A, Obara M, Fujimoto K, Endo T, Nishio M, Kondo T, Hashino S, Tanaka J, Asaka M, Imamura M. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. *Bone Marrow Transplant* 2012, 47:258-264.
 30. Abe J, Ueha S, Yoneyama H, **Shono Y**, Kurachi M, Goto A, Fukayama M, Tomura M, Kakimi K, Matsushima K. B cells regulate antibody responses through the medullary remodeling of inflamed lymph nodes. *Int Immunol* 2011, 24:17-27.
 31. Arita K, Kondo T, Sugita J, Shigematsu A, Shiratori S, Wakasa K, Yasumoto A, Ibata M, **Shono Y**, Kikuchi M, Goto H, Takeda Y, Takahata M, Kato N, Nishio M, Ota S, Tanaka J, Imamura M. Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. *Int J Hematol* 2011, 94:291-295.
 32. **Shono Y**, Kosugi-Kanaya M, Shiratori S, Sugita J, Fujimoto K, Kondo T, Nishio M, Tanaka J, Imamura M. Donor cell leukemia after umbilical cord blood transplantation: recurrent or de novo? The importance of diagnosis for therapeutic decision making. *Int J Hematol* 2011, 93:563-565.
 33. Shiratori S, Kondo T, Fujisawa S, Kubota K, Kosugi M, **Shono Y**, Sugita J, Fujimoto K, Nishio M, Tanaka J, Koike T, Matsuno Y, Matsuno K, Asaka M, Imamura M. c-myc rearrangement in B-cell lymphoblastic lymphoma with the involvement of multiple extranodal lesions. *Leuk Lymphoma* 2011, 52:716-718.
 34. Asanuma S, Tanaka J, Sugita J, Kosugi M, Shiratori S, Wakasa K, **Shono Y**, Shigematsu A, Kondo T, Kobayashi T, Asaka M, Imamura M. Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common γ -chain cytokines (IL-2 and IL-15) and rapamycin. *Ann Hematol* 2011, 90:617-624.

35. **Shono Y**, Ueha S, Wang Y, Abe J, Kurachi M, Matsuno Y, Sugiyama T, Nagasawa T, Imamura M, Matsushima K. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. *Blood* 2010, 115:5401-5411. (Commentary in *Blood* 2010, 115:5284-5285, Featured in *Science-Business eXchange (SciBX)*, doi:10.1038/scibx.2010.476).
36. Toubai T, Paczesny S, **Shono Y**, Tanaka J, Lowler KP, Malter CT, Kasai M, Imamura M. Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. *Curr Stem Cell Res Ther* 2009, 4:252-259.
37. Toubai T, **Shono Y**, Tone S, Ibata M, Kato N, Malter C, Lowler KP, Ota S, Tanaka J, Asaka M, Imamura M. Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation. *Leuk Lymphoma* 2009, 50:844-847.
38. Toubai T, **Shono Y**, Nishihira J, Ibata M, Suigita J, Kato N, Ohkawara T, Tone S, Lowler KP, Ota S, Tanaka J, Asaka M, Reddy P, Imamura M. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. *Int J Lab Hematol* 2009, 31:161-168.
39. Tanaka J, Sugita J, Asanuma S, Arita K, **Shono Y**, Kikutchi M, Shiratori S, Wakasa K, Yasumoto A, Shigematu A, Kondo T, Kobayashi T, Asaka M, Imamura M. Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation. *Hum Immunol* 2009, 70:701-705.
40. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, **Shono Y**, Kitabatake M, Kakimi K, Mukaida N, Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. *Blood* 2008, 111:5457-5466.
41. Toubai T, Hirate D, **Shono Y**, Ota S, Ibata M, Mashiko S, Sugita J, Shigematsu A, Miura Y, Kato N, Umehara S, Kahata K, Iwao N, Toyoshima N, Tanaka J, Asaka M, Imamura M. Chimerism and T cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma. *Int J Lab Hematol* 2008, 30:75-81.
42. Toubai T, **Shono Y**, Imamura M. The pathophysiology of acute graft-versus-host disease in allogeneic hametopoietic stem cell transplantation. *Res. Adv. in Hematology* 2007,

2:35-51.

43. Kaji M, Takana J, Sugita J, Kato N, Ibata M, **Shono Y**, Ota S, Kondo T, Asaka M, Imamura M. Ciprofloxacin inhibits lipopolysaccharide-induced toll-like receptor-4 and 8 expression on human monocytes derived from adult and cord blood. *Ann Hematol* 2008, 87:229-231.
44. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, **Shono Y**, Ota S, Kondo T, Asaka M, Imamura M. Regulation of the expression of MHC class-I related chain A, B(MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. *Leukemia* 2007, 21:2103-2108.
45. Tanaka J, Sugita J, Kato N, Toubai T, Ibata M, **Shono Y**, Ota S, Kondo T, Kobayashi T, Kobayashi M, Asaka M, Imamura M. Expansion of NK receptor(CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit. *Exp Hematol* 2007, 35:1562-1566.
46. Toubai T, Tanaka J, Ota S, Shigematsu A, **Shono Y**, Ibata M, Hashino S, Kondo T, Kakinoki Y, Masauzi N, Kasai M, Iwasaki H, Kurosawa M, Asaka M, Imamura M. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. *Intern Med* 2007, 46:3-9.
47. **Shono Y**, Tanaka J, Toubai T, Ota S, Ibata M, Mashiko S, Hirate D, Miura Y, Umehara S, Toyoshima N, Asaka M, Imamura M. Abnormal expansion of naive B lymphocytes after unrelated cord blood transplantation- a case report. *Clin Lab Haematol* 2006, 28:351-354.
48. Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, **Shono Y**, Morioka M, Kawamura T, Masauzi N, Kakinoki Y, Kobayashi H, Kunieda Y, Kasai M, Kurosawa M, Imamura M. Effect of granulocytes colony stimulating factor on decreased IL-12 p40 production during chemotherapy for B-cell lineage Non-Hodgkin's lymphoma patients. *Eur J Haematol* 2006, 77:403-9.
49. Toubai T, Tanaka J, Nishihira J, Ohkawara T, Hirate D, Kondo N, Tone S, **Shono Y**, Iwao N, Imamura M. Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation. *Transplant Immunol* 2006, 16:117-124.
50. Toubai T, Tanaka J, Ota S, Mori A, Ibata M, **Shono Y**, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M. Successful

reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy. *Intern Med* 2005, 44:476-479.

51. Toubai T, Tanaka J, Higa T, Ota S, Ibata M, **Shono Y**, Mashiko S, Miura Y, Umehara S, Kahata K, Toyoshima N, Morioka M, Asaka M, Kasai M, Imamura M. Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities. *Am J Hematol* 2005, 78:67-70.